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To  review  the  latest  information  about  levels  of  anti-tuberculosis  (TB)  drug  resistance  in the  European
Region  of the  World  Health  Organization  (WHO)  and time-trends  in  multidrug-resistant  TB  (resistance
to  isoniazid  and rifampicin;  MDR-TB)  over  the  past ﬁfteen  years.
We analysed  data  on  drug  resistance  among  new  and  previously  treated  TB  cases  reported  from  1997 to
2012.  Data  are collected  in  surveys  of  representative  samples  of  TB patients  or from  surveillance  systems
based  on diagnostic  drug  susceptibility  testing.
A total  of 15.7%  (95%  conﬁdence  limits  (CI):  9.5–21.9)  of new  and  45.3%  (95%CI:  39.2–51.5) of previously
treated  TB cases  are  estimated  to  have  MDR-TB  in  the  Region.  Extensively  drug-resistant  TB  (MDR-TB
and  resistance  to  ﬂuoroquinolones  and  second-line  injectables;  XDR-TB)  had  been  reported  by  38 of
the  53  countries  of the  region  (72%).  The  proportion  of MDR-TB  cases  with  XDR-TB  is  11.4%  (95%CI:
8.6–14.2).  Between  1997  and 2012,  population  rates  of  MDR-TB  declined  in Estonia,  Latvia  and  Germany
and  increased  in the United  Kingdom,  Sweden  and  Tomsk  Oblasts  of  the Russian  Federation.
Surveillance  of  drug  resistance  has  been  strengthened  in  the  WHO  European  Region,  which  has  the
highest  proportions  of  MDR-TB  and  XDR-TB  ever  reported  globally.  More  complete  data  are needed
particularly  from  the  Russian  Federation.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. Open access under CC BY-NC-ND license.ontents
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. Introduction
Resistance to anti-tuberculosis (TB) drugs represents a public
ealth problem worldwide (Abubakar et al., 2013). The emergence
nd spread of drug-resistant Mycobacterium tuberculosis strains
as been documented since the early years of the introduction
f chemotherapy for the treatment of TB, largely associated with
nadequate treatment (Medical Research Council, 1948) and is
ften worsened by poor airborne infection control measures in
ealth care facilities and congregate settings (Kompala et al., 2013).
lobally, a total of 450 000 (range 300 000–600 000) people are
stimated to have contracted multidrug-resistant TB (MDR-TB;
esistance to at least rifampicin and isoniazid) in 2012 (WHO,
013a,b,c). Among them, approximately one quarter occurred in
ountries of the European Region of the World Health Organization
WHO). In several of these countries, an alarmingly high proportion
f TB patients have MDR-TB: up to half of all cases in some settings
ithin the former Soviet Union (Jenkins et al., 2013; Skrahina et al.,
012; Zignol et al., 2012).
Patients  with MDR-TB require longer, expensive and more toxic
reatment regimens and are less likely to be cured compared
ith those with drug-susceptible TB (Falzon et al., 2011, 2013).
lthough policy guidance on the programmatic management of
rug resistant-TB (Falzon et al., 2011) and control of the trans-
ission of resistant strains (WHO, 2009a,b) has been developed
y WHO, national TB control programmes face major challenges in
etecting and treating MDR-TB and in controlling the development
nd spread of drug-resistant TB. These include limited diagnostic
apacity, shortages of high-quality medicines, insufﬁcient numbers
f health care professionals properly trained to care for patients
ith MDR-TB, and suboptimal infection control measures in health
are facilities and congregate settings (Falzon et al., 2013).
To  address the problem of drug resistance in the WHO  European
egion, a consolidated action plan to prevent and combat MDR-TB
nd extensively drug-resistant TB (XDR-TB; MDR-TB with addi-
ional resistance to a ﬂuoroquinolone and a second-line injectable)
WHO, 2011a,b) and a roadmap to prevent and combat drug-
esistant TB (WHO, 2011a,b) have been developed. The Plan aims
o contain the spread of drug-resistant TB by achieving univer-
al access to prevention, diagnosis and treatment of MDR-TB and
DR-TB in all countries of the Region. Surveillance of resistance
o anti-TB drugs is a fundamental component of the strategy to
ontrol drug-resistant TB, since it allows the proportion of cases
ith drug resistance in a population to be monitored and, conse-
uently, assessment of the effectiveness of prevention and control
easures. This information can in turn be used to plan appro-
riate measures for early detection, design effective treatment
egimens, assess epidemiological trends, and to promptly identify
nd respond to outbreaks (Zignol et al., 2011).
In this article, we review the latest available information about
evels of anti-TB drug resistance in the WHO  European Region and
ime-trends in MDR-TB over the past ﬁfteen years.
.  Methods
The WHO  European Region includes 53 Member States
Tables 1 and 2).
Drug  resistance surveillance data have been collected from spe-
ial surveys and/or continuous surveillance conducted between
997 and 2012. Special surveys are epidemiological studies
esigned to measure drug resistance among a representative sam-
le of notiﬁed patients with pulmonary TB. Continuous surveillance
s based on routine diagnostic drug susceptibility testing (DST) of
ll bacteriologically conﬁrmed TB patients (WHO, 2009a,b; Zignol
t al., 2012). The following three main principles, discussed in detailpdates 16 (2013) 108–115 109
elsewhere (WHO, 2009a,b; WHO, 2010; Zignol et al., 2011), are used
by WHO  to ensure quality and representativeness of surveillance
data on anti-TB drug resistance: (a) data should be representative
of TB cases in the country or geographical setting under study;
(b) drug resistance among new TB cases should be clearly distin-
guished from drug resistance among previously treated TB cases;
and (c) laboratory methods for DST should be selected from among
those that are endorsed by WHO  and laboratory results should be
quality-assured. Only data collected according to these principles
were used in our analyses. A global network of 29 Supranational TB
Reference Laboratories controls the quality of DST results; nearly
half of them (14/29) are in the WHO  European Region (STOP TB
Partnership, 2013; Van Deun et al., 2011).
Aggregated data from special surveys were collected by WHO
using a standard data collection form while continuous surveillance
data were captured on an annual basis through the electronic “WHO
global TB data collection system” (WHO, 2013a,b,c). WHO  classi-
ﬁes the survey and continuous surveillance data according to their
quality and representativeness using criteria detailed elsewhere
(WHO, 2009a,b, 2010, 2013a,b,c) based on coverage of culture and
DST services among TB patients. Data on resistance to rifampicin
and isoniazid were assessed to measure the proportion of cases
with MDR-TB. Among conﬁrmed cases of MDR-TB, data were col-
lected to measure the frequency of XDR-TB.
The proportions of new and previously treated TB cases with
MDR-TB, the proportion of MDR-TB cases with XDR-TB, the propor-
tion of MDR-TB cases with resistance to any ﬂuoroquinolone, and
the proportion of MDR-TB cases with resistance to any second-line
injectable agent were calculated for each country. The proportion of
MDR-TB cases with ﬂuoroquinolone resistance and the proportion
of MDR-TB cases with resistance to second-line injectable agents
discussed in this paper include also XDR-TB cases. Robust stan-
dard errors were used where data from sub-national areas were
available for multiple years (Spain). Country estimates for coun-
tries with subnational level data only (the Russian Federation and
Spain) and regional estimates were then derived using random
effects logistic regression, with the country (or setting in case of
country estimates) as a cluster. All analyses were performed using
Stata (Version 12; Stata Corp. LP, College Station, USA).
The  MDR-TB rate is deﬁned as the annual number of estimated
new MDR-TB cases per 100 000 population (UN, 2013). MDR-TB
rates between 1997 and 2012 were calculated by multiplying the
notiﬁcation rate of new TB cases reported annually to WHO  (WHO,
2013a,b,c) by the proportion of MDR-TB among new TB cases
reported in the same setting and year. These data points were plot-
ted in MS  Excel and exponential lines were ﬁtted. The average
annual percentage change in the rate of MDR-TB was calculated
for settings where anti-TB drug resistance had been measured in at
least ﬁve different years.
3.  Findings
3.1. Coverage of anti-TB drug resistance surveillance
Fig. 1 shows the coverage of surveillance of drug resistance in
the WHO  European Region. Drug resistance data were available
from 51 of the 53 countries of the WHO  European Region. The two
exceptions were Monaco and San Marino, where cases of TB have
been notiﬁed only sporadically over the past ﬁfteen years; these
two countries were therefore not included in our analyses. Most
countries with surveillance data (88%; 45/51) have continuous
surveillance systems. The remaining six countries (Armenia, Azer-
baijan, Romania, Tajikistan, Turkmenistan and Uzbekistan) have
relied on special surveys of representative samples of patients.
Nationwide and population-representative data were available
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Table  1
MDR-TB among new and previously treated cases, by country, the WHO  European Region.
Country Yeara New cases Previously treated cases Number of country-year
data  points
Cases w ith DST
results  (H + R)
MDR-TB % (95%
CI)b
Cases w ith DST
results  (H + R)
MDR-TB % (95%
CI)b
Albania 2012 172 0.6 15 0.0 3
Andorra  2011 1 0.0 1 0.0 11
Armenia  2007 552 9.4(7.0–12.4) 340 43.2 (37.9–48.7) 1
Austria  2011 257 3.5 11 18.2 13
Azerbaijan  (Baku city) 2007 551 22.3(18.6–26.6) 552 55.8 (49.7–62.4) 1
Belarus  2012 2164 34.8 1183 68.6 3
Belgium  2011 524 1.3 35 11.4 13
Bosnia  and Herzegovina 2011 704 0.1 41 9.8 12
Bulgaria  2012 687 2.3 142 23.2 2
Croatia  2011 353 0.3 40 2.5 9
Cyprus  2011 25 4.0 2 0.0 8
Czech  Republic 2011 392 1.5 16 6.3 14
Denmark  2011 257 1.2 14 0.0 14
Estonia  2012 193 19.7 46 50.0 16
Finland  2012 206 1.5 14 0.0 15
France  2009 2890 0.5 106 13.2 13
Georgia  2012 1931 9.2 541 31.2 5
Germany  2012 2198 1.5 116 10.3 16
Greece  2010 115 0.9 15 6.7 4
Hungary  2010 474 2.1 80 8.8 2
Iceland  2012 4 0.0 1 100.0 14
Ireland  2012 190 1.1 17 0.0 13
Israel  2012 318 4.7 6 33.3 15
Italy  2011 760 4.0 441 5.4 12
Kazakhstan  2012 8154 22.9 10443 55.0 3
Kyrgyzstan  2012 504 26.4 662 68.4 1
Latvia  2012 666 11.1 100 32.0 16
Lithuania  2012 1017 11.4 350 44.0 14
Luxembourg  2011 7 0.0 1 0.0 9
Malta  2012 13 0.0 1 0.0 11
Monaco
Montenegro  2012 58 0.0 5 0.0 8
Netherlands  2012 628 1.6 28 3.6 16
Norway  2011 229 1.3 22 0.0 14
Poland  2012 4073 0.5 535 2.1 6
Portugal  2011 1155 1.5 97 5.2 13
Republic  of Moldova 2012 1264 23.7 933 62.3 3
Romania  2004 849 2.8(1.8–4.2) 382 11.0(80.–14.6) 2
Russian  Federation (39
Federal Subjectsc)
2011 23.1 48.6 1–11e
San Marino
Serbia 2012 716 0.8 83 3.6 7
Slovakia  2012 142 0.0 27 3.7 14
Slovenia  2012 114 0.0 12 0.0 15
Spain  (Aragon, Catalonia
and  Galicia regions)
2005  0.2 7.1 1–9e
Sweden 2012 453 2.4 24 8.3 15
Switzerland  2012 246 1.2 31 12.9 15
Tajikistan  2011d 544 12.5(9.8–15.6) 496 56.0 1
The  Former Yugoslav
Republic  of Macedonia
2012  155 0.0 26 15.4 4
Turkey  2012 4742 3.2 641 21.8 1
Turkmenistan (Aral Sea
region)
2002  105 3.8(1.1–9.5) 98 18.4(11.3–27.5) 1
Ukraine  2012 11185 14.4 5925 32.2 1
United  Kingdom of Great
Britain  and Northern
Ireland
2011  4549 1.3 234 5.6 14
Uzbekistan  2011 705 23.2(17.8–29.5) 332 62 (52.5–70.7) 1
CI = conﬁdence interval; DST = drug susceptibility testing; H + R = isoniazid plus rifampicin.
a Data from the most recent year are shown.
b CI are displayed only for countries that conducted a survey.
c The 39 Federal Subjects are: Adygea Republic, Arkhangelsk Oblast, Belgorod Oblast, Bryansk Oblast, Chukotka Autonomous Okrug, Chuvasia Republic, Ivanovo Oblast,
Kaliningrad Oblast, Kamchatka Krai Oblast, Karelia Republic, Kemerovo Oblast, Khabarovsk Krai, Khakassia Republic, Komi Republic, Kostroma Oblast, Leningrad Oblast,
Magadan Oblast, Mary-El Republic, Murmansk Oblast, Nizhni Novgorod Oblast, Novgorod Oblast, Omsk Oblast, Orel Oblast, Penza Oblast, Primorsky Krai, Pskov Oblast, Sakha
(Yakutia)  Republic, Sakhalin Oblast, Samara Oblast, Tambov Oblast, Tomsk Oblast, Trans-Baikal Krai (Chita Oblast), Tula Oblast, Tver Oblast, Ulyanovsk Oblast, Vladimir Oblast,
Vologda  Oblast, Voronezh Oblast, and Yamalo-Nents Autonomous Okrug.
d Data on previously treated cases refer to the year 2012.
e For countries without national level data but for which data are available for more than one subnational area, the range of area-year data points is shown.
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Table  2
Resistance to second-line anti-TB drugs among MDR-TB cases, by country, the WHO  European Region.
Country Yeara MDR-TB
cases
MDR-TB  cases w ith
DST  results for
2nd-line  drugs
Resistance to
ﬂuoroquinolones
Resistance to
second-line
injectable  agents
XDR-TB
Number
of cases
%  (95% CI)b Number
of cases
%  (95% CI)b Number
of cases
%  (95% CI)b
Albania 2010 2 2 0 0.0 0 0.0 0 0.0
Andorra
Armenia  2007 199 199 25 12.6(8.3–18.0) 10 5.0 (2.4–9.0)
Austria  2011 19 19 8 42.1 8 42.1 6 31.6
Azerbaijan  (Baku
city)
2007 431 431 125 29.0 (24.8–33.5) 55 12.8(9.8–16.3)
Belarus  2011 612 612 128 20.9(17.8–24.4) 235 38.4 (34.5–42.4) 73 11.9(9.5–14.8)
Belgium  2011 15 15 4 26.7 7 46.7 3 20.0
Bosnia  and
Herzegovina
2011 5 5 0 0.0 0 0.0 0 0.0
Bulgaria  2012 49 49 6 12.2 6 12.2 5 10.2
Croatia
Cyprus  2011 1 1 0 0.0 0 0.0 0 0.0
Czech  Republic 2011 7 5 3 60.0 3 60.0 2 40.0
Denmark  2011 3 2 0 0.0 0 0.0 0 0.0
Estonia  2012 61 55 12 21.8 10 18.2 4 7.3
Finland  2012 3 3 1 33.3 2 66.7 1 33.3
France
Georgia  2012 346 341 51 15.0 149 43.7 30 8.8
Germany
Greece  2010 2 2 0 0.0 1 50.0 0 0.0
Hungary  2010 18 18 4 22.2 2 11.1 2 11.1
Iceland  2012 1 1 1 100.0 0 0.0 0 0.0
Ireland  2012 1 1 0 0.0 0 0.0 0 0.0
Israel  2012 17 17 4 23.5 6 35.3 4 23.5
Italy  2011 81 50 6 12.0
Kazakhstan
Kyrgyzstan
Latvia  2012 106 106 21 19.8 61 57.5 17 16.0
Lithuania  2012 271 210 68 32.4 90 42.9 52 24.8
Luxembourg
Malta  2007 1 1 0 0.0
Monaco
Montenegro 2011 1 1 0 0.0 1 100.0 0 0.0
Netherlands  2007 6 6 0 0.0
Norw  ay 2011 4 4 0 0.0 1 25.0 0 0.0
Poland  2008 52 52 9 17.3 3 5.8 5 9.6
Portugal  2007 34 33 7 21.2
Republic  of
Moldova
Romania
Russian  Federation
(Tomsk  Oblast)
2005 201 201 11 5.5
San  Marino
Serbia 2012 5 5 0 0.0 1 20.0 0 0.0
Slovakia  2012 1 1 0 0.0 0 0.0 0 0.0
Slovenia
Spain  (Cataluna
region)
2005 4 4 0 0.0
Sw  eden 2012 14 14 2 14.3 2 14.3 2 14.3
Switzerland 2012 8 8 0 0.0 1 12.5 0 0.0
Tajikistan
(Dushanbe  city
and  Rudaki
district)
2009 100 100 25 25.0(16.9–34.7) 21 21 (13.5–30.3)
The  Former
Yugoslav
Republic of
Macedonia
2010 7 5 1 20.0 1 20.0 1 20.0
Turkey  (Ankara
city)
2011 8 8 1 12.5 1 12.5 0 0.0
Turkmenistan
Ukraine
United  Kingdom of
Great  Britain and
Northern  Ireland
2011 81 79 19 24.1 16 20.3 6 7.6
Uzbekistan  2011 370 319 23 7.2(4.6–10.6) 63 19.7(15.5–14.5) 17 5.3(3.1–8.4)
CI = conﬁdence interval; DST = drug susceptibility testing; H + R = isoniazid plus rifampicin.
a Data from the most recent year are shown.
b CI are displayed only for countries that conducted a survey.
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OFig. 1. Coverage of surveillance of dru
rom almost all countries; the exceptions were Azerbaijan, the
ussian Federation, Spain and Turkmenistan for which data were
vailable for certain geographic areas that are not considered rep-
esentative of the country as a whole. At the time of writing,
ationwide surveys are ongoing in Azerbaijan and Turkmenistan
hich are expected to produce country-representative data by
arly 2014. For Spain, surveillance data are available from three
egions (Aragon, Catalonia and Galicia) and for the Russian Feder-
tion, high-quality data were available from 39 out of 83 Federal
ubjects1 that cover approximately one third of the country’s pop-
lation (Ministry of Health of the Russian Federation, 2013). Nearly
ll countries have recent surveillance data. In Romania, where the
ast survey dates from 2004 (Stoicescu et al., 2008), a new survey
s planned for 2014.
.2.  Multidrug-resistant tuberculosis (MDR-TB)
The proportion of new TB cases with MDR-TB ranged from 0%
o 34.8% (Fig. 2; Table 1) and was above 20% in Azerbaijan (22.3%
n 2007), Belarus (34.8% in 2012), Kazakhstan (22.9% in 2012),
yrgyzstan (26.4% in 2012), the Republic of Moldova (23.7% in
012), the Russian Federation (average: 23.1%, with Yamalo-Nenets
utonomous Area being the highest: 41.9% in 2011) (Ministry of
ealth of the Russian Federation, 2013) and Uzbekistan (23.2% in
011).
Levels of drug resistance remain very low (<3% in new cases) in
ost western European countries.
The proportion of previously treated TB cases with MDR-TB
t the country level ranged from 0% to 68.6% for those countries
eporting more than 10 previously treated cases in 2012 (Fig. 3
nd Table 1). Countries or subnational areas with the highest
eported proportions were Azerbaijan (Baku city: 55.8% in 2007),
elarus (68.6% in 2012), Estonia (50.0% in 2012), Kazakhstan (55.0%
n 2012), Kyrgyzstan (68.4% in 2012), the Republic of Moldova
62.3% in 2012), Tajikistan (56.0 in 2012) and Uzbekistan (62.0%
n 2011). In the Russian Federation, where the overall proportion
f MDR-TB among previously treated cases was 48.6%, the propor-
ion exceeded 50% in 12 (30%) of the 39 reporting Federal Subjects,
eaching 74.0% in 2011 in Ulyanovsk Oblast (Ministry of Health of
he Russian Federation, 2013).
1 The 39 Federal Subjects with high quality surveillance data on drug resis-
ance  are: Adygea Republic, Arkhangelsk Oblast, Belgorod Oblast, Bryansk Oblast,
hukotka Autonomous Okrug, Chuvasia Republic, Ivanovo Oblast, Kaliningrad
blast,  Kamchatka Krai Oblast, Karelia Republic, Kemerovo Oblast, Khabarovsk Krai,
hakassia Republic, Komi Republic, Kostroma Oblast, Leningrad Oblast, Magadan
blast,  Mary-El Republic, Murmansk Oblast, Nizhni Novgorod Oblast, Novgorod
blast,  Omsk Oblast, Orel Oblast, Penza Oblast, PrimorskyKrai, Pskov Oblast, Sakha
Yakutia) Republic, Sakhalin Oblast, Samara Oblast, Tambov Oblast, Tomsk Oblast,
rans-Baikal Krai (Chita Oblast), Tula Oblast, Tver Oblast, Ulyanovsk Oblast, Vladimir
blast, Vologda Oblast, Voronezh Oblast, and Yamalo-Nents Autonomous Okrug.stance in the WHO  European Region.
Combining data from all countries of the Region, 15.7% (95% con-
ﬁdence limits: 9.5–21.9) of new and 45.3% (95%CI: 39.2–51.5) of
previously treated TB cases were estimated to have MDR-TB.
3.3.  XDR-TB and resistance to second-line drugs
XDR-TB had been reported by 38 countries in the Region
(72% of all countries) by the end of 2012. Surveillance data on
resistance to ﬂuoroquinolones and injectable agents (amikacin,
kanamycin and/or capreomycin) among cases with MDR-TB were
reported from 39 out of the 51 countries for which drug resis-
tance surveillance data were available (76%). Combining data from
all countries, the proportion of MDR-TB cases with resistance to
ﬂuoroquinolones, second-line injectable agents and XDR-TB was
20.1% (95% CI: 15.2–25.1), 34.2% (95% CI: 26.7–41.6) and 11.4% (95%
CI: 8.6–14.2), respectively. A total of 41.1% (95% CI: 32.3–50.0) of
patients with MDR  had resistance to either a ﬂuoroquinolone or a
second-line injectable agent or to both.
Of the 39 reporting countries, ﬁve could report data only from
a subnational setting (13%). Only 9 (23.6%) reported more than 10
XDR-TB cases; among these, proportions of XDR-TB among MDR-
TB cases exceeded 10% in Azerbaijan (Baku city: 12.8% in 2007),
Belarus (11.9% in 2011), Latvia (16.0% in 2012), Lithuania (24.8%
in 2012) and Tajikistan (Dushanbe city and Rudaki district: 21.0%
in 2009). Proportions of resistance to ﬂuoroquinolones, injectable
agents and XDR-TB by country are shown in Table 2.
3.4.  Trends in drug resistance
Of  the 51 countries with surveillance data, 8 had data from only
one single survey or one year of surveillance (Armenia, Azerbaijan,
Kyrgyzstan, Tajikistan, Turkey, Turkmenistan, Ukraine and Uzbek-
istan). Thirty four of the remaining 43 countries (79%) had data for
5 or more years, although for the Russian Federation and Spain data
are from subnational areas only (Table 1). Fig. 4 shows data from a
group of selected countries or territories with 5 or more data points
where well-deﬁned time trends could be observed. Three distinct
epidemiological situations are documented. In the ﬁrst group of
countries, Estonia, Latvia and Germany, notiﬁcation rates of new
TB cases are decreasing and estimated notiﬁcation rates of MDR-
TB are also decreasing (at 4%, 4% and 5% per year, respectively).
In the second group of countries, including Georgia, Lithuania, and
Arkhangelsk Oblast, notiﬁcation rates are decreasing and MDR-TB
rates are stable or slightly increasing. In the last group, including
United Kingdom, Sweden and Tomsk Oblasts of the Russian Feder-
ation, both TB and MDR-TB rates are increasing with MDR-TB rates
rising faster than TB notiﬁcation rates (5%, 11% and 13% per year,
respectively).
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Fig. 2. Percentage of new TB cases with MDR-TBa, in the WHO  European Region. a Figures are based on the most recent year for which data have been reported, which varies
among countries.
Fig. 3. Percentage of previously treated TB cases with MDR-TBa, in the WHO  European Region. a Figures are based on the most recent year for which data have been reported,
which varies among countries. Note that the high percentage of previously treated TB cases with MDR-TB in Iceland refers to only one notiﬁed previously treated case.
Fig. 4. Rates per 100,000 population of new TB cases (black circles) and MDR-TB among new TB patients (red circles) in selected countries that represent three major types
of  epidemiological pattern in the European Region, 1997–2012. The mean percentage change per year is given as a percentage. (For interpretation of the references to color
in  this ﬁgure legend, the reader is referred to the web version of the article.)
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. Discussion
Enormous progress has been achieved over the past three years
n the WHO  European Region in improving the coverage and
uality of surveillance of anti-TB drug resistance. In 2010, nation-
ide representative data on levels of MDR-TB were not available
rom Albania, Azerbaijan, Belarus, Bulgaria, Kyrgyzstan, the Rus-
ian Federation, Spain, Tajikistan, Turkey, Turkmenistan, Ukraine
nd Uzbekistan (WHO, 2010). Since then, nationwide surveys have
een completed in Albania (WHO, 2012), Belarus (Skrahina et al.,
013), Bulgaria (WHO, 2012), Kyrgyzstan (WHO, 2012), Tajikistan
WHO, 2012), and Uzbekistan (Ulmasova et al., 2013). Several coun-
ries have strengthened their national surveillance systems based
n routine diagnostic DST of all bacteriologically conﬁrmed TB
atients and now generate high quality anti-TB drug resistance
urveillance data, including Albania, Belarus, Bulgaria, Kazakhstan,
epublic of Moldova, Turkey and Ukraine (WHO, 2013a,b,c). Fol-
owing the completion of the national surveys currently underway
n Azerbaijan and Turkmenistan, almost all countries in the Region
ill have nationally representative measurements of the burden of
DR-TB available, with the only exception being the Russian Fed-
ration among the countries with high TB burden. Although the
umber of Federal Subjects in the Russian Federation for which
igh quality surveillance data were available has rapidly increased
n recent years, from 12 in 2008 to 39 in 2011 (Ministry of Health
f the Russian Federation, 2013; WHO, 2010), the magnitude of
he drug resistance burden is not known for approximately two
hirds of the country’s population. This is due to poor coverage
f culture and DST services in parts of the country and the sub-
ptimal quality of laboratory results. In addition to strengthening
he surveillance system, the country should consider conducting
 national survey to gain a more comprehensive understanding
f the baseline levels of drug resistance across the entire popu-
ation.
Of the 27 countries making up the European Union (EU), 25
lready report nationally representative data based on continuous
urveillance (diagnostic DST for all TB patients). In Spain, surveil-
ance needs to be extended beyond the 3 (of 17) autonomous
ommunities that are covered.
The  proportions of TB cases with MDR-TB in countries of east-
rn Europe and central Asia remain the highest recorded globally
nd are of great concern (WHO, 2013a,b,c; Zignol et al., 2012).
ith between one third and one half of all TB cases in several
f these countries having MDR-TB, a new approach to TB and
DR-TB control is clearly warranted. In recognition of this urgent
eed, a consolidated action plan to prevent and combat MDR-TB
nd XDR-TB in the WHO  European Region, covering the ﬁve years
011–2015, was developed, and subsequently endorsed by all WHO
ember States (WHO, 2011a,b). It is believed that due to ongoing
ransmission and latent MDR-TB infection, the proportion of new
ases that have MDR-TB may  not decrease in the near future. There-
ore the Plan targets for the end of 2015 are to decrease by 20%
oints (compared with 2011) the proportion of previously treated
B patients that have MDR-TB by improving the effectiveness of TB
reatment provided by national programmes, to diagnose ≥85% of
ll estimated MDR-TB patients and to treat successfully ≥75% of all
atients notiﬁed with having MDR-TB.
The burden of MDR-TB is expected to fall as the overall burden of
B falls with economic development. It is worth noting that the Rus-
ian Federation, the country with the highest share of the MDR-TB
urden in the region, has recently become a high-income country
nd one that reports spending US $1.5 billion per year on TB control
WHO, 2013a,b,c). Like the Russian Federation, other eastern Euro-
ean and central Asian countries are experiencing fast economic
rowths which are expected to bring progressive reduction of the
urden of TB and MDR-TB.pdates 16 (2013) 108–115
It is commendable that three quarters of the countries in the
European Region have surveillance data on second-line drug resis-
tance in patients with MDR-TB. However, most of the countries in
eastern Europe and central Asia with the highest burdens of MDR-
TB and XDR-TB have limited or no information on the levels and
patterns of second-line anti-TB drug resistance, or can provide only
data collected during subnational surveys that have never been
repeated (Table 2). Establishing high quality continuous surveil-
lance systems based on routine testing of resistance to second-line
drugs for all patients with MDR-TB should be a priority in all
countries with a high burden of anti-TB drug resistance. This neces-
sitates strengthening laboratory capacity to conduct second-line
DST, which remains suboptimal in most non-EU countries. In addi-
tion, recording and reporting of XDR-TB should become mandatory
in all countries, particularly in the Russian Federation and other for-
mer  Soviet Union countries where XDR-TB cases are not routinely
recorded and reported.
Despite  the lack of second-line anti-TB drug resistance surveil-
lance data from several countries with a high burden of MDR-TB,
overall proportions of XDR-TB and of resistance to ﬂuoroquinolones
and second-line injectable agents amongst MDR-TB cases in the
region are higher than the global averages (WHO, 2013a,b,c). More
than 40% of MDR-TB patients have additional resistance to either a
ﬂuoroquinolone, a second-line injectable agent or both and would
therefore be eligible to receive bedaquiline, a new bactericidal drug
recently approved for use in patients with MDR-TB when options
to treat this condition using existing drugs have been exhausted
(WHO, 2013a,b,c).
The  experience of the Baltic States, which were considered a
hotspot of MDR-TB in the 1990s (Aziz et al., 2006; Espinal et al.,
2001), suggests that MDR-TB can be controlled once economic and
social development is combined with bold policy decisions and
implementation of appropriate prevention and control measures.
Our analysis of trends shows that where both TB and MDR-TB rates
are falling, MDR-TB is falling less quickly than the TB case notiﬁca-
tion rate, and that when both TB and MDR-TB rates are increasing,
MDR-TB is climbing more rapidly than the TB case notiﬁcation rate.
There was no setting in which TB rates increased while the MDR-
TB rates decreased. These ﬁndings illustrate three important points.
First, that it is easier to control drug-susceptible TB compared with
drug-resistant forms of TB. Secondly, and partly as a result, that at
least in some settings, drug-susceptible TB may  be slowly replaced
by MDR-TB. Thirdly, that when TB rates increase in the European
Region there is also a concomitant increase in MDR-TB rates. In
Sweden and the United Kingdom, the rise in MDR-TB notiﬁcation
rates is largely due to migration from high MDR-TB burden coun-
tries (Devaux et al., 2010).
Most  TB patients of foreign origin – particularly those from the
eastern part of Europe – are at increased risk of being infected with
a drug-resistant Mycobacterium tuberculosis strain compared with
native TB cases. When investigating presumptive TB patients who
originate from a high MDR-TB burden country, it is recommended
to use a rapid molecular test to predict rifampicin resistance as
a ﬁrst-line test (Weyer et al., 2013). Measures to limit transmis-
sion of MDR-TB within the country and across borders are needed
which are suited to the current level and pattern of international
migration (Dara et al., 2012). Very high costs are associated with
management of TB and drug-resistant TB disease in countries of the
European Region (Diel et al., 2014). Greater investments are needed
by high income countries in research and development as well as in
the health systems of less afﬂuent countries to help achieve better
TB control and limit the propagation of drug-resistant TB strains
within their borders and throughout the Region.
Ensuring that all patients with MDR-TB are diagnosed and
treated is of paramount importance for prevention and control of
MDR-TB but this should not be the only measure. Treatment for
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DR-TB and XDR-TB is long and associated with signiﬁcant tox-
cities and, globally, only slightly more than half of those started
n treatment successfully complete their course of therapy (Falzon
t al., 2013). It is therefore critical to invest resources in the
revention of MDR-TB, including ensuring that all patients with
usceptible TB are treated according to international standards
Migliori et al., 2012) and infection control practices are properly
mplemented, particularly in health care and congregate settings
WHO, 2009a,b, 2011a,b).
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